106 related articles for article (PubMed ID: 12454706)
1. Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Au WY; Ma SK; Chung LP; Chim CS; Kwong YL
Ann Hematol; 2002 Nov; 81(11):659-61. PubMed ID: 12454706
[TBL] [Abstract][Full Text] [Related]
2. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
Tavernier E; Thomas X
Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
[TBL] [Abstract][Full Text] [Related]
3. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
5. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
[TBL] [Abstract][Full Text] [Related]
6. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
7. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
8. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
9. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
10. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
11. Biology and management of therapy-related acute promyelocytic leukemia.
Lo-Coco F; Hasan SK; Montesinos P; Sanz MA
Curr Opin Oncol; 2013 Nov; 25(6):695-700. PubMed ID: 24076582
[TBL] [Abstract][Full Text] [Related]
12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
13. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
14. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
16. [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone].
Mochiduki Y; Muramoto S
Rinsho Ketsueki; 2005 Nov; 46(11):1218-22. PubMed ID: 16440807
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
18. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Al Bahar S; Pandita R; Bavishi K; Kreze O
Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
[TBL] [Abstract][Full Text] [Related]
19. Curative therapeutic approaches to APL.
Tallmann MS
Ann Hematol; 2004; 83 Suppl 1():S81-2. PubMed ID: 15124685
[TBL] [Abstract][Full Text] [Related]
20. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
Raza S; Ullah K; Ahmed P; Khan B
J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
